Disclosure & Disclaimer

Disclosure -

By way of disclosure, I currently invest in the stem cell sector, including some public companies mentioned in this Blog. My extended family are also market investors. As part of their diversified portfolios they hold stocks, mostly via managed accounts in funds and in blue chip holdings. I have recommended stocks over the years in a variety of sectors - including biotech & stem cells, in which they may at times hold positions in. 

Disclaimer -

Nothing in this blog or elsewhere constitutes a recommendation to buy securities in companies that have publicly traded stock or the like. Please consult your financial advisor should you consider a company mentioned in this Blog or elsewhere by the writer interesting as an investment. All research noted is freely provided and does not represent itself as accurate or fact but merely a perspective based on individual research. All content should be viewed as public information only and should be double checked by the reader for their own purposes. All imagery, video, audio and written work is the property of their respective copyright owners.   

1 comment:

  1. The stem cell assay market based on cell type is segmented into human embryonic stem cells and adult stem cells. The largest share of the global Stem Cell Assay market is occupied by the adult stem cell segment this can be credited to the increasing research in the field of regenerative medicine and favorable government policies and regulation. On the basis of type, the Stem Cell Assay market is segmented into differentiation assay, viability/cytotoxicity assay cell identification, proliferation assay and other assay. The viability/cytotoxicity assay segment is likely to dominate the market with the largest share of the stem cell assay market; this can be credited to the widespread research in the stem cell arena and need to determine viable cells from non-viable stem cells.
    Read More: https://www.marketindustryreports.com/stem-cell-assay-market/8